MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT05287191

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05287191
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05287191. Randomized; single masking; primary purpose treatment. Start 2022-01-05 (actual); primary completion 2025-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care
Acronym
MAGNAM
Condition
Atrial Fibrillation New Onset
Intervention (Drug)
Magnesium sulfate and then Digoxin
Intervention (Drug)
Amiodarone
Lead sponsor
Sunnybrook Health Sciences Centre (class: other)
Collaborator
Sunnybrook Research Institute (class: other)

Record details

Record id
cardio:ct-nct05287191
Content hash
a6217ea5117405f59a9ad45944c5633d17508035e753138b097bcbe8063b2a44